Advertisement

Increased Frequency of Topical Steroids Provides Benefit in Patients With Recalcitrant Postsurgical Macular Edema

Published:April 06, 2017DOI:https://doi.org/10.1016/j.ajo.2017.03.033

      Purpose

      To compare standard and frequent topical steroids for postsurgical macular edema (ME).

      Design

      Randomized clinical trial.

      Methods

      Subjects with postsurgical ME stratified into post–cataract surgery ME (PCSME) and post–other surgery ME (POSME) were randomized to ketorolac 4 times a day (qid) + 1% prednisolone acetate (PA) every hour while awake (q1hWA, Group 1) or qid (Group 2). Mean change from baseline best-corrected visual acuity (BCVA) was determined at week 12, after which group 2 subjects with persistent edema were crossed over to PA q1hWA.

      Results

      Twenty-two subjects (13 PCSME and 9 POSME) were randomized to Group 1 and 20 (12 PCSME and 8 POSME) to Group 2. At week 12, change from baseline BCVA (ETDRS letters) in Group 1 vs 2 was +11.6 vs +8.5 (P = .32) and for subgroups was +10.6 vs +7.8 (P = .23) for PCSME and +13.1 vs +9.4 (P = .47) for POSME. Mean change from baseline central subfield thickness (CST, μm) at week 12 in Group 1 vs 2 was −100.8 vs −63.9 (P = .30). Mean change from baseline intraocular pressure was +2.6 vs +1.7 mm Hg (P = .52). Eight subjects in Group 2 with residual ME at week 12 were switched to PA q1hWA and at week 24, the mean changes from week 12 BCVA and CST were +7.0 letters (P = .01) and −108.25 μm (P = .04).

      Conclusions

      Our data suggest that patients with postsurgical ME should initially be treated with ketorolac and PA qid, but if edema does not resolve after 12 weeks, a switch to ketorolac qid and PA q1hWA may provide benefit.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to American Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nguyen Q.D.
        • Shah S.M.
        • Van Anden E.
        • et al.
        Supplemental inspired oxygen improves diabetic macular edema; a pilot study.
        Invest Ophthalmol Vis Sci. 2003; 45: 617-624
        • Nguyen Q.D.
        • Tatlipinar S.
        • Shah S.M.
        • et al.
        Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.
        Am J Ophthalmol. 2006; 142: 961-969
        • Campochiaro P.A.
        • Hafiz G.
        • Shah S.M.
        • et al.
        Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator.
        Mol Ther. 2008; 16: 791-799
        • Nguyen Q.D.
        • Shah S.M.
        • Heier J.S.
        • et al.
        Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study.
        Ophthalmology. 2009; 116: 2175-2181
        • Nguyen Q.D.
        • Brown D.M.
        • Marcus D.M.
        • et al.
        Ranibizumab for diabetic macular edema. results from 2 phase iii randomized trials: RISE and RIDE.
        Ophthalmology. 2012; 119: 789-801
        • Elman M.J.
        • Aiello L.M.
        • et al.
        • The Diabetic Retinopathy Clinical Research Network
        Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
        Ophthalmology. 2010; 117: 1064-1077
        • Korobelnik J.F.
        • Do D.V.
        • Schmidt-Erfurth U.
        • et al.
        Intravitreal aflibercept for diabetic macular edema.
        Ophthalmology. 2014; 121: 2247-2254
        • Flach A.J.
        The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery.
        Trans Am Ophthalmol Soc. 1998; 96: 557-634
        • Lobes Jr., L.A.
        • Grand M.G.
        Incidence of cystoid macular edema after scleral buckling procedure.
        Arch Ophthalmol. 1980; 98: 1230-1239
        • Meredith T.A.
        • Reeser F.H.
        • Topping T.M.
        • Aaberg T.M.
        Cystoid macular edema after retinal detachment surgery.
        Ophthalmology. 1980; 87: 1090-1095
        • West C.E.
        • Fitzgerald C.R.
        • Sewell J.H.
        Cystoid macular edema following aphakic keratoplasty.
        Am J Ophthalmol. 1973; 75: 77-81
        • Michels R.G.
        • Ryan Jr., S.J.
        Results and complication of 100 consecutive cases of pars plana vitrectomy.
        Am J Ophthalmol. 1975; 80: 24-31
        • Chu C.J.
        • Johnston R.L.
        • Buscombe C.
        • et al.
        Risk factors and incidence of macular edema after cataract surgery: a database study of 81,984 eyes.
        Ophthalmology. 2016; 123: 316-323
        • Miyake K.
        Prophylaxis of aphakic cystoid macular edema using topical indomethacin.
        J Am Intraocul Implant Soc. 1978; 4: 174-179
        • Kraff M.C.
        • Sanders D.R.
        • Jampol L.M.
        • et al.
        Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin.
        Ophthalmology. 1982; 89: 885-890
        • Yilmaz T.
        • Cordero-Coma M.
        • Gallagher M.J.
        Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review.
        Eye (Lond). 2012; 26: 252-258
        • Gass J.D.
        • Norton E.W.
        Cystoid macular edema and papilledema following cataract extraction.
        Arch Ophthalmol. 1966; 76: 646-661
        • Gass J.D.M.
        • Norton E.W.D.
        Follow-up study of cystoid macular edema following cataract extraction.
        Trans Am Acad Ophthalmol Otolaryngol. 1969; 73: 665-682
        • Benhamou N.
        • Massin P.
        • Haouchine B.
        • et al.
        Intravitreal triamcinolone for refractory pseudophakic macular edema.
        Am J Ophthalmol. 2003; 135: 246-249
        • Jonas J.B.
        • Kreissig I.
        • Degenring R.F.
        Intravitreal tiramcinolone acetonide for pseudophakic cystoid macular edema.
        Am J Ophthalmol. 2003; 136: 384-386
        • Williams G.A.
        • Haller J.A.
        • Kuppermann B.D.
        • et al.
        Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome.
        Am J Ophthalmol. 2009; 147: 1048-1054
        • The Early Treatment Diabetic Retinopathy Study Research Group
        Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1.
        Arch Ophthalmol. 1985; 103: 1796-1806
        • Irvine S.R.
        A newly defined vitreous syndrome following cataract surgery.
        Am J Ophthalmol. 1953; 36: 599-619
        • Foster C.S.
        • Davanzo R.
        • Flynn T.E.
        • et al.
        Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis.
        J Ocul Pharmacol Ther. 2010; 26: 475-483
        • Slabaugh M.A.
        • Herlihy E.
        • Ongchin S.
        • van Gelder R.N.
        Efficacy and potential complications of difluprednate use for pediatric uveitis.
        Am J Ophthalmol. 2012; 153: 932-938

      Linked Article